Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Day One ... - Markets Insider

Retrieved on: 2024-06-20 14:33:39

Tags for this article:

Click the tags to see associated articles and topics

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Day One ... - Markets Insider. View article details on hiswai:

Excerpt

Currently, the analyst consensus on Day One Biopharmaceuticals is a Moderate Buy with an average price target of $41.78, representing a 245.9% upside.

Article found on: markets.businessinsider.com

View Original Article